Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial

BACKGROUND: NVX-CoV2373 is a recombinant severe acute respiratory coronavirus 2 (rSARS-CoV-2) nanoparticle vaccine composed of trimeric full-length SARS-CoV-2 spike glycoproteins and Matrix-M1 adjuvant. METHODS AND FINDINGS: The phase 2 component of our randomized, placebo-controlled, phase 1 to 2 t...

Descripción completa

Detalles Bibliográficos
Autores principales: Formica, Neil, Mallory, Raburn, Albert, Gary, Robinson, Michelle, Plested, Joyce S., Cho, Iksung, Robertson, Andreana, Dubovsky, Filip, Glenn, Gregory M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486115/
https://www.ncbi.nlm.nih.gov/pubmed/34597298
http://dx.doi.org/10.1371/journal.pmed.1003769

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486115/
https://www.ncbi.nlm.nih.gov/pubmed/34597298
http://dx.doi.org/10.1371/journal.pmed.1003769

Ejemplares similares